复方中兽药超微粉治疗鸡大肠杆菌病效果研究

Efficacy of TCM compound superfine powder against chicken colibacillosis

为验证复方中兽药超微粉对鸡大肠杆菌病的治疗效果,在进行鸡大肠杆菌标准菌株O78攻毒剂量筛选基础上,以该菌株进行攻毒造模。实验设超微粉、细粉制剂、阳性药物和空白对照等7组,经过15 d实验,结果表明,中兽药超微粉3个剂量组(A、B、C组)的死亡率均显著低于(P<0.01或P<0.05)阳性药物对照组和感染对照组(E、F),中兽药超微粉3个剂量组(A、B、C组)与中兽药细粉组(D组)比较差异显著(P<0.05);中兽药超微粉3个剂量组治愈率和有效率(A、B、C组)均显著高于(P<0.01或P<0.05)阳性药物对照组和感染对照组(E、F),细粉和阳性药物对照组(D、E)比较差异不显著(P>0.05);增重效果与上述分析结果大致相同。A、B、C 3组相比,无论是死亡率,还是治愈率、有效率、增重情况看,A、B两组均优于C组,但A、B两组间差异不显著(P>0.05)。考虑到用药量、成本效益等综合因素,确定该中兽药超微粉治疗鸡大肠杆菌病临床推荐用量为0.5 g/kg体重拌料。

In order to verify efficacy of TCM compound superfine powder against chicken colibacillosis, chicken model was established with E.coli standard strain O78.After 15 days of testing, the results showed that chicken mortality in TCM compound superfine powder treated groups(A, B and C) was significantly lower(P<0.01 or P<0.05) than that of fine powder treated group(D), positive drug control group(E) and infection control group(F). Meanwhile the curative rate and effective rate of group A,B and C group was significantly lower(P <0.01 or P <0.05) than that of group E and F, and group D had no difference with group E(P >0.05). Effect on weight gain was roughly the same as the above analysis. Based on the analysis of mortality,curative rate, efficiency and weight gain situation, both of group A and B was better than C group, but there was no difference between group A and B(P >0.05). Taking into account the dosage, cost, and benefit and so on, the clinical recommended dosage was 0.5 g/kg by mixing in feedstuff.